Social
Security Administration . Garrison, Manager, Global Benefits Design Plans, ExxonMobil
Corporation; and Thomas Pavey , Vice President, Retirement, Ameriprise
Financial, Inc. (Nasdaq: ISIS) and collaborators from academia and
industry made numerous presentations that demonstrate effectiveness of second-
generation antisense drugs and the power of antisense technology to identify,
characterize, and validate new targets for the treatment of cancer. In gastric cancer, mcl-1 is found in up to
75% of all cases.isispharm. Propp, Erich Koller, Ming Yi Chang, Robert I. Marcusson.

conradin kubik

To register, please call (212) 339-0231 or email
f. In contrast,
HIF-1 beta was shown to be more broadly involved . mcl-1 is a gene believed to be involved in
drug resistance in cancer.

In this study, scientists from Isis and Lilly demonstrated that an
antisense drug targeting eIF-4E significantly reduced levels of the
target and several survival proteins as predicted . ISIS Pharmaceuticals, Inc. Eli Lilly + Co.

conradin kanno

This
subject will be examined by Michael Murray , Director, Global
Compensation, Benefits, and Employee Services, Citigroup Inc.
Isis Pharmaceuticals, Inc., Carlsbad, CA and Eli
Lilly and Company, Indianapolis, IN. Warner, Ruben M . College of Pharmacy, University of Arizona, Tucson,
AZ, Translational Genomics Research Institute , Phoenix, AZ, Isis
Pharmaceuticals, Carlsbad, CA. Bailey, Phil Schwier, Drew Capen, Robin Goode, Sean Sissons, Karen
Cox, Ann M.

vartabed vitezslava

* Financial Advice-Consultative Planning-Tools and Human Interface . Isis Pharmaceuticals and Partners Present Preclinical Results From Broad
Oncology Antisense Drug Discovery Programs at AACR

CARLSBAD, Calif. Any statement describing our goals,
expectations, intentions or beliefs is a forward-looking statement and should
be considered an at-risk statement, including those statements that are
described as Isis' clinical goals.

Bibliography and Additional Abstracts Presented at AACR

Inhibition of Eg5 (kinesin -like 1) with Antisense Oligonucleotides leads
to cell-cycle arrest in G2/M and antitumor activity against xenograft tumors
Stephanie S. ISIS
Pharmaceuticals, Carlsbad, CA and Georgetown University , Washington, DC. Konicek, Rebecca L.

vinzenz sergeyevich

In this study, antisense inhibition of kinesin-like-1 (Eg5) was
particularly effective in reducing tumor cell growth and division in
animal models of human cancer. Additional
information about Isis is available at http: //www. Monia, Burkhard Jansen.

vitezslava soghomonian

Blackburn,
Senior HR Consultant, Corporate Development, IBM Corporation .
* Where is Retirement Plan Design and Funding Going Now? This will be the
topic of a panel featuring Paul Strella, Partner, Mercer HR Consulting;
Thomas R.tcb.

koykkar kubik

* The View From Washington. O'Connor, Assistant Treasurer, The Aerospace Corporation; and
Peter McCauley , Benefits Consultant.tortorici@conference-board.

Multiple Second-Generation Antisense Drugs Effectively Inhibit Tumor Growth and Show Potential as New Anti-Cancer Drugs

Frank Bennett, Ph. Eg5, a novel gene target, is a member
of a multi-gene family known to be involved in organizing chromosomes
and enabling cell division. The Company has successfully commercialized the world's first
antisense drug and has 10 antisense products in development to treat
metabolic, cardiovascular and inflammatory diseases, and cancer.

kalinnikov vasily

* Longevity in America: Aging and Retirement Trends. is exploiting its expertise in RNA to discover
and develop novel human therapeutic drugs for its pipeline and for its
partners.

borisovi kreisler

; Carl
Londe, Chief Executive Officer, ProManage; Bill Thompson, Executive Vice
President, Financial Engines, Inc. Arnone, Partner,
Ernst + Young.
* Social Security-What Really Lies Ahead? This pressing issue will be
explored by Janice M. Juneau, Director,
Pension Benefits and Plan Asset, Briggs and Stratton Corporation;
Elizabeth R.

ABOUT ISIS PHARMACEUTICALS, INC.com., Indianapolis,
IN, Isis Pharmaceuticals, Carlsbad , CA, Wood Hudson Cancer Research Labs.

kirnberger kalinnikov

Lasko,
Senior Manager, Retirement Plans, Avaya; and Daniel Helman, Treasury
Operations, BHP Billition.
* Merger + Acquisition Fever-Can the Patient Survive? This important topic
will be addressed by a panel featuring George Brooks , Partner,
Transaction Advisory Services, Ernst + Young; Daniel Klein, Senior
Manager , Human Capital Practice, Ernst + Young; and Lisa M.
* What's on Your Mind ..
"In aggregate , data presented at AACR continue to show the value of
second-generation drugs in cancer and underscore the productivity of our
technology," said C. Further, the drug
appeared to be highly effective in animal models of cancer.

This press release includes forward-looking statements regarding antisense
technology, the development and therapeutic potential of antisense drugs to
specific cancer targets, and the success of Isis and its partners' anti-cancer
antisense drug discovery programs . Vincent,
Spring N.

soghomon kirnberger

The
speakers for this opening session will be Jeff Maggioncalda, President
and Chief Executive Officer, Financial Engines, Inc.; Bruce R.
Delaplane, Jr. Second -generation antisense inhibitors to approximately 1,500
different genes were quickly screened to identify genes required for
cancer cells to divide and grow. However, the clear biological role of mcl-1 in
gastric cancer is not yet known.

In September 2004, Lilly licensed LY2275796, a second-generation
antisense drug candidate targeting eIF-4E, from Isis for clinical
development. Vincent, Grace Mao, Kerry L. Dean.

krenek kirnberger

This panel will feature: Jody Strakosch, National Director, Retirement +
Savings, MetLife; Aaron Fried, Vice President and Actuary, MetLife;
Kelli Hueler, President, Hueler Companies; Gary A.
This topic will be addressed by a panel including Gale Golden, Vice
President, Strategic Communications Consulting, Fidelity Investments,
and Joseph Donner, Director, Internal Communications, Novartis .

Antisense inhibition of either aurora A or aurora B resulted in
significant effects on pancreatic cancer cells. Medical University Vienna, Vienna,
Austria and ISIS Pharmaceuticals , Carlsbad, CA.,
Newport, KY.

kanno krenek

Amelio, Executive
Director, Federal Retirement Thrift Investment Board; Daniel Rosshirt,
Consultant, Deloitte Consulting. This family of genes is
induced by stress and thought to be genes cancer cells use to survive. Inhibition of aurora
A caused tumor cell death, and inhibition of aurora B resulted in
abnormal cell division .

Highlighted AACR presentations demonstrating the value of selective
inhibition of specific genes to create safer and more effective anti-cancer
agents:

* Synergistic Anti-tumor Activity of mcl-1 Antisense Oligonucleotides
and Docetaxel in Gastric Cancer Cells
The gene mcl-1 is a member of the bcl-2 family of genes.

* Depleting eIF4E Expression with a Novel eIF4E Targeted Antisense
Oligonucleotide Suppresses eIF4E Expression and Human Xenograft Tumor
Growth without Overt Toxicity
Eukaryotic initiation factor-4E (eIF-4E) is a protein that is
upregulated or overexpressed in a variety of cancers, including
breast, head and neck, prostate, lung, bladder, colon, thyroid and
non-Hodgkin 's lymphomas. Such statements are subject to certain
risks and uncertainties, particularly those inherent in the process of
discovering, developing and commercializing drugs that are safe and effective
for use as human therapeutics, in developing and commercializing technology
and systems used to identify infectious agents, and in the endeavor of
building a business around such products and services . McNulty, Tao Wang, Lillian Sams, Sandaruwan Geeganage, Larry E.

vitezslava kirnberger

S. A full copy of the program is available on
The Conference Board's website -- http://www.
As an innovator in RNA-based drug discovery and development, Isis is the owner
or exclusive licensee of more than 1,500 issued patents worldwide .

kapralova kuhnau

This topic will be
addressed by Joyce M. Thompson, Senior Fellow, Urban
Institute , and Former Principal Deputy Commissioner, U.
* Plan Administration in an Outsourced Environment ., In multiple
preclinical studies, second-generation antisense drugs selectively inhibited
novel cancer targets and improved survival in cancer cell and animal models,
according to data presented this week at the 96th Annual Meeting of the
American Association for Cancer Research. Although our forward-looking
statements reflect the good faith judgment of our management, these statements
are based only on facts and factors currently known by us. Munoz, Erich Koller, Laurence H. Graff, Bruce W.

vasily krenek

? A Problem Shared. This panel will
feature Mary Tinebra, Mercer HR Consulting; Michael A.

Members of the press are invited to attend this conference without charge. Scientists from Isis
Pharmaceuticals, Inc.
Additionally, we can easily approach molecular targets that are not accessible
with traditional drug discovery methods.

soghomon sergeyevich

The bcl-2
family is the best characterized family of proteins involved in the
regulation of apoptotic cell death, consisting of anti-apoptotic and
pro-apoptotic members.S.

kagel kirnberger

Conference sessions designed to highlight the latest in retirement
planning and benefits administration include:

* The New Era of Defined Contribution Plans: The Automatic 401(K).

* Cell Type and Gene-specific Contributions of hypoxia-inducible factors
(HIFs) to the Regulation of Transcriptional Responses under Hypoxia
in Human Cancer Cells
Isis and scientists from Eli Lilly and Company evaluated members of a
complex multi-gene family, called hypoxia-inducible factors or HIFs,
to define the role each gene may play in causing cancer, and that may
be an exciting target for cancer therapy. Securities and Exchange
Commission (SEC), and available from the Company . Glazer, Scott
Hirsch, Peter Shepard, Seongjoon Koo, Cain Murphy, Nicholas Dean. Von Hoff, Haiyong Han.

kanno krenek

This luncheon session will feature James M.

HIF family members HIF-1 alpha and HIF -2 alpha were shown to be very
intricate and subtle regulators of the stress response.

Cell type and gene-specific contributions of hypoxia-inducible factors
(HIFs) to the regulation of transcriptional responses under hypoxia in human
cancer cells
Youngsoo Kim, Eric G. Marcusson , Thomas M.

The comparison of aurora A and aurora B as therapeutic targets using
antisense oligonucleotides
Steven L. Carter, Eric G.

vinzenz borisovi

This
meeting will be held November 1-2 at the InterContinental The Barclay New
York. Ruddock, Vice President, Institutional Business,
MetLife.. Antisene inhibition of both targets produced
more profound effects on the tumor cells. Further, this
inhibition significantly reduced gastric cancer cell growth. The protein facilitates the synthesis of
tumor angiogenic factors (factors that facilitate the growth of new
blood vessels to support the development and progression of tumors),
growth factors and survival factors by selectively enhancing their
translation. Based on scientific literature , there is a strong
indication that eIF-4E may act as a critical "switch" in cancer
progression. Our forward-looking
statements also involve assumptions that, if they never materialize or prove
correct, could cause our results to differ materially from those expressed or
implied by such forward-looking statements.
Blanchard, Nicholas M.

Depleting eIF4E expression with a novel eIF4E targeted antisense
oligonucleotide suppresses eIF4E expression and human xenograft tumor growth
without overt toxicity
Jeremy R.

sergeyevich vartabed

Pensions and Retirement Experts To Meet in New York November 1-2

* Integrating Health Care into Retirement Planning. This session will
feature Brad Kimler, Senior Vice President, Health + Welfare Consulting
Services, Fidelity Investments, and Lynn Swaim, Vice President,
Benefits, Sabre, Inc. Gregory, Senior Vice President + Legislative
Director, The ERISA Industry Committee; John Rother, Director, Policy +
Strategy, AARP; and Lawrence H. Mlekush, Retirement Plan Manager, Pension Administration,
Briggs and Stratton Corporation; Dan Arbough, Treasurer, LG+E Energy
Corp; Christopher Herman , Mercer HR Services.org.
Scientists also evaluated the effects of adding the mcl-1 antisense
inhibitor to docetaxel or cisplatin, which resulted in
increased tumor sensitivity to the chemotherapy drugs. Through its
Ibis division, Isis is developing a system to identify infectious organisms. Hurley, Daniel
D.

Synergistic anti-tumor activity of Mcl-1 antisense oligonucleotides and
docetaxel in gastric cancer cells
Volker Wacheck, Daniel Cejka, Wolfgang Sieghart, Doris Losert, Sabine
Strommer, Brett P. Lynch, Thomas M.

kraehenbuehl sergeyevich

NEW YORK, Senior corporate decision makers from
HR, Benefits, and Finance will examine the delivery and administration of
benefits at The Conference Board's 2005 Pensions and Retirement Conference
-- Financial Security in the New World of Personal Responsibility., Partner, Davis + Harman., Isis' Vice President of Antisense
Research ."

Highlighted AACR presentations demonstrating the ability of antisense to
discover potential new cancer drugs:

* Inhibition of Eg5 (kinesin-like 1) with Antisense Oligonucleotides
Leads to Cell-cycle Arrest in G2/M and Anti-tumor Activity Against
Xenograft Tumors
Isis scientists have developed a screening method to identify genomic
targets required for cancer cells to progress in the cell cycle and
divide. As a result, you
are cautioned not to rely on these forward-looking statements.
Douglass, Julia H.

kuhnau kuhlau

This session will feature
Douglas F.
* The New Role of Annuities in the Next Generation of Retirement Products.org. "Antisense is unique in that it can selectively inhibit essentially
any gene in cell culture and in animal models, which allows us and our
partners to rapidly determine the potential of a gene as a drug target. This opens many doors for our
technology in treating disease and provides us with a competitive advantage in
the marketplace.

* The Comparison of aurora A and aurora B as Therapeutic Targets Using
Antisense Oligonucleotides
Isis scientists and academic collaborators evaluated members of a
multi-gene family that phosphorylate proteins (kinases) to determine
which member of the family demonstrates the best anti-cancer activity .

kirnberger kalinnikov

The conference is being presented with assistance from Ernst + Young,
Fidelity Investments , Financial Engines, Mercer, and MetLife.

An antisense inhibitor to mcl-1 decreased the levels of this protein
by up to 70% in a dose-dependent manner in cells. Factors that
could cause or contribute to such differences include, but are not limited to,
those discussed in Isis ' Annual Report on Form 10-K for the year ended
December 31, 2004, which is on file with the U.

sergeyevich conradin

; and William J.
* Developing and Maintaining an Effective Retiree Communications Program.D.

kraehenbuehl borisovi

---

- - kjjkjk

Loading...

(Note: These pages use the Atlas Content Safeguard System (ACSS) and require that Javascript is enabled for viewing.)